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Abstract
Reduced somatotrophic signaling through the growth hormone (GH) and insulin-like growth factor pathways (IGF1) can delay aging, 
although the degree of life-extension varies markedly across studies. By collating data from previous studies and using meta-analysis, we tested 
whether factors including sex, hormonal manipulation, body weight change and control baseline mortality quantitatively predict relative life-
extension. Manipulations of GH signaling (including pituitary and direct GH deficiencies) generate significantly greater extension in median 
life span than IGF1 manipulations (including IGF1 production, reception, and bioactivity), producing a consistent shift in mortality risk of 
mutant mice. Reduced Insulin receptor substrate (IRS) expression produces more similar life-extension to reduced GH, although effects are 
more heterogeneous and appear to influence the demography of mortality differently. Life-extension with reduced IGF1 signaling, but neither 
GH nor IRS signaling, increases life span significantly more in females than males, and in cohorts where control survival is short. Our results 
thus suggest that reduced GH signaling has physiological benefits to survival outside of its actions on circulating IGF1. In addition to these 
biological moderators, we found an overrepresentation of small sample sized studies that report large improvements in survival, indicating 
potential publication bias. We discuss how this could potentially confound current conclusions from published work, and how this warrants 
further study replication.
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Extension of life span through mammalian genetic mutation was 
first demonstrated in Ames Dwarf mice (1). These animals have a 
pituitary deficiency, resulting in extremely low levels of growth hor-
mone (GH), prolactin and thyroid stimulating hormone. This initial 
finding generated a strong interest in the role of the GH signaling 
pathway in aging, and downstream effects of reduced somatotrophic 
signaling, particularly changes in insulin and insulin-like growth 
factor I (IGF1) signaling. A possible link between aging and IGF1/
insulin signaling in mammals was particularly exciting because 
related signals in invertebrates also influence aging (2), indicating 
evolutionarily conserved molecular mechanisms (3). Furthermore, 
polymorphisms in these pathways in humans have been associated 
with long life (4).
Manipulations that reduce GH signaling at a number of differ-
ent levels have been shown to extend mouse life span. Snell Dwarf 
mice have a similar deficiency in pituitary development to Ames 
Dwarf mice and can live longer than controls in particular condi-
tions (5). Targeted disruption of the GH receptor can also extend 
mouse life span (6), as can disruption of growth-hormone releasing 
hormone production (7). While interference in several aspects of 
GH signaling appear to consistently affect mouse life span, manipu-
lations of insulin and IGF1 signaling have produced mixed life-span 
effects. The majority of circulating IGF1 is produced in the liver, 
and exerts its cellular effects through binding to the IGF1 recep-
tor, although there is substantial cross-reactivity between IGF1 and 
insulin with each binding to the other’s receptor, albeit at lower 
affinities. Heterozygous deletion of the IGF1 receptor (IGF1R+/−) 
was initially shown to extend life span (8), but only significantly 
in female mice. However, later replication of this work by both 
the same group (9) and a different group (10) reported a much 
milder life-span phenotype (although still significant in females) 
using different genetic backgrounds. Mice with adult liver-specific 
inactivation of IGF1 production show some extension in life span 
(11), again, only significantly in females, as do animals with loss 
of pregnancy-associated plasma protein-A expression (12), a zinc 
metalloproteinase that enhances the bioactivity of IGF1. Genetic 
inhibition of insulin receptor substrate proteins (IRS I and IRS II), 
downstream of IGF-IR, can also extend life span: homozygous dele-
tion of IRS I extends life span (13,14), although heterozygous dele-
tion of IRS II was reported to extend life span in one study (15) but 
not another (13).
The inconsistency of life-span extension with these genetic mod-
els has been a subject of much discussion, with authors arguing that 
differences in macronutrient composition of diet, body weight, sex, 
health status, and survival profile of control groups could explain 
variation in life-span extension (9,10,16–20). However, most discus-
sions have centered on qualitative comparisons between two single 
studies, limiting the ability to ascertain whether differences in results 
are a consequence of specific differences in study design. Life span 
responses to manipulations can differ considerably between laborato-
ries even when the same strain and source of mice is used, and explicit 
effort has been made to match variables such as light cycle, hous-
ing temperature and environmental enrichment (21,22). Differences 
between laboratories in life-span responses with the same genetic 
manipulation might therefore simply be the result of unrelated labo-
ratory specific variation and/or represent sampling error or measure-
ment errors.
In an effort to better explain variation in life-span responses 
to GH-IGF1-IRS manipulation, we conducted a meta-analysis. 
We collated data from available published studies that examined 
life span in animals with genetic manipulations of these signaling 
pathways in comparison to unmanipulated controls. Our data col-
lection protocol resulted in 42 different control-treatment survival 
comparisons, and cumulated survival data from 2,460 individuals. 
This allowed us to provide a quantitative test of whether life-span 
extension is greater with particular types of manipulation, and 
whether variation in responses is consistently related to previously 
suggested variables such as sex, survival of control groups, or rela-
tive changes in body weight. We were unable to look at effects of 
dietary composition on life-span extension in these models, due 
to inadequate information in some studies, and we urge authors 
to provide such information in future experiments. By collating 
data from different studies, we were also able to provide an insight 
into the demographic causes of life-span extension. It has been sug-
gested that life-span extension with reduced GH signaling delays 
the onset of aging, but does not impact its rate once it starts (23). 
The problem is that quantifying such a change requires a large 
sample size, usually not possible with individual mouse studies. 
Our meta-analytic approach provides the power to access how 
life-span extension through altered GH-IGF1-IRS signaling arises 
demographically.
Results
Increased Survival With Reduced Somatotrophic 
Signaling
Across all studies reduced pituitary, GH, IGF1, and IRS signaling 
extended median life span by on average 157  days, 21.6%, with 
the overall meta-analytic hazard rate at median life span for mutant 
animals significantly lower than that of controls (the log hazard 
ratio, lnHR50 = −0.87, 95% confidence interval, CI [−1.17, −0.57], 
z = −5.65, p < .0001). While this effect is substantial and significant, 
there is a high level of heterogeneity between studies (Q41 = 78.6, 
p =  .0004, I2 = 56.0%). Part of this heterogeneity is explained by 
splitting animals according to the underlying signals/hormones that 
are manipulated (test of moderator: QM2  = 10.53, p  =  .005, mar-
ginal R2 or R2[m] = 55.5%, which is heterogeneity accounted by the 
three signaling categories, sensu (24)). Animals with mutations that 
predominately alter GH signaling (also including other pituitary 
hormones in Ames and Snell Dwarf mice; see Table  1 for models 
included in different moderator groups) show greater relative reduc-
tions in mortality (Figure 1A) when compared to the reduction in 
mortality generated by mutations that interfere with either IGF1 or 
IRS. Notably, the degree of heterogeneity in response to manipu-
lation further differed among the three subgroups, with GH/pitui-
tary manipulations also showing the least heterogeneity in life-span 
response, while IRS manipulations show the highest (GH: 5.6%, 
IGF: 34.1%; IRS: 47.2%; Figure 1A). We note here that data from 
IRS manipulations is derived from only three different studies. The 
substantial heterogeneity observed within this category might partly 
result from a lack of concordance between two studies for one par-
ticular mouse model (IRS2+/−), and there has been less independent 
replication with each mouse model than those GH/pituitary studies. 
We also tested whether strain (seven different strain variants in the 
full set) explained variance across the dataset, but the proportion of 
variance explained was negligible (6.7% for lnHR50 and ~0% for the 
models analyzing demography presented below).
It has previously been qualitatively noted that life-span exten-
sion in Ames-Dwarf mice occurs predominately through a shift in 
the age at which age-associated mortality becomes apparent (25). A 
more recent study of mortality changes with reduced IGF1 signal-
ing, however, suggested a decrease in the rate of aging when serum 
IGF1 levels are lowered (26). To understand whether these effects 
are consistent across different genetic models of reduced somato-
trophic signaling, we assessed alterations in Gompertz parameters of 
mortality across available mouse data. Fitting Gompertz (m(t) = a + 
exp(bt)) models to life-span data separates parameter b, the “aging 
rate” of the population (the rate of increase in mortality over time, 
t), and parameter a, which describes the vulnerability to dying from 
ageing related causes (27,28).
Table 1. Animal Models Included in Each Moderator Category
Moderator Category Animal Models Included
Growth hormone/pituitary manipulation Ames & Snell Dwarfs, GH Receptor −/−, GH releasing hormone −/−, GH antagonist
Insulin like growth factor 1 (IGF1) IGF1R+/−, liver-specific IGF1−/−, Pregnancy associated plasma protein A (PPAP-A), IGF1 hypomorphic 
allele
Insulin receptor substrate (IRS) IRS1−/−, IRS1+/−, IRS2+/−
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There was a significant overall change in parameter a in mutant 
mice compared to controls across all animal models (lnHRa = 
−0.88, 95% CI [−1.63, −0.13], z = −2.30, p = .02), although mice 
with mutations disrupting different hormonal signals showed dif-
ferent changes in this demographic parameter (test of moderator: 
QM2 = 10.11, p = .006, R
2
[m] = 65.1%, Figure 1B). Considering 
only mice with manipulations of pituitary/GH signaling, param-
eter a is substantially reduced (Figure 1B, p < .01), generaliz-
ing the effect previously noted by Bartke et al. (25). Mice with 
manipulations in IGF1 signaling show a similar change although 
the effect across all studies is non-significant (Figure 1B, p = .05). 
When IRS signaling is manipulated, however, this parameter is sig-
nificant with a sign in the opposite direction (Figure 1B, p = .047; 
see also Supplementary Table S1). We therefore might expect a 
modulation of ageing rate with reduced IRS signaling to be the 
demographic cause of life-extension. When examining changes in 
the rate of aging—parameter b—there is a significant reduction 
in this parameter with reduced IRS signaling (p < .01), with no 
change in this parameter in GH and IGF1 mutant mice (Figure 1C, 
Supplementary Table S1). There also appears to be lower heteroge-
neity surrounding the Gompertz estimates for reduced IRS signal-
ing that those other manipulations, which could indicate a more 
consistent effect on the demography of mortality. However, we are 
again cautious of interpretation of this result given the lower level 
of replication for these models.
The Sex-Specificity of Life-span Extension
There has been growing recognition that interventions extending life 
span have sex-specific effects (17,29). Reduced IGF1 signaling has 
been reported to have a stronger life-extending effect in females than 
males in several studies (8,10). Reduced pituitary/GH signaling has 
also been qualitatively noted to extend life span to a greater extent 
in females (1,30). To understand whether any of these sex-specific 
effects are a consistent feature of life-span extension through altered 
somatotrophic signaling, and/or differ in severity across different 
manipulation types, we tested whether sex was a significant predictor 
of life-span extension. When including all studies life-span extension 
is significantly stronger in females than males (while including hor-
monal manipulation type as moderator, see above: lnHR[male] = 0.31, 
95% CI [0.04, 0.57], z = 2.24, p = .025).
However, this sex effect was only significant with IGF1 manipu-
lations (lnHR[male] = 0.45, 95% CI [0.09, 0.81]) but not those of pitu-
itary/GH signaling or IRS (lnHR[male] = 0.09, 95% CI [−0.43, 0.62], 
lnHR[male] = 0.07, 95% CI [−0.54, 0.68], respectively, Figure 1A).
The Relationship Between Life-span Extension and 
Body Mass
Most interventions that extend life span in mice typically reduce 
body weight, and this reduced growth allocation may contribute to 
life-span extension (31). To quantify how relative changes in body 
estimate (log hazard ratio) from meta-analysis of Gompertz 
estimate from meta-analysis of 
log hazard ratio at median lifespan 
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Figure 1. Life-span extension with reduced somatotrophic signaling. (A) The log-hazard ratio for median life span in each of the three moderator groups. 
Negative values indicate increased survival in the mutant group. (B & C) The log-hazard ratio for Gompertz parameters in each moderator group. (D) The 
relationship between change in body mass and change in life span for GH/pituitary and IGF1 mutant animals.
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weight relate to life-extension we extracted data on body mass from 
the papers used in our longevity analyses above, and from associ-
ated publications. Most data was available for young animals 
(~3 months; although little was available for IRS manipulated ani-
mals and these were excluded from this analysis), so we restricted 
our analysis to that period, but note that these data are well cor-
related to measurements at 12 months of age (for the data available: 
rs = .73, n = 15, p = .002). Manipulations that reduce IGF1 signaling 
tended to reduce body weight (the log response ratio, lnRR = −0.23, 
95% CI [−0.49, 0.03]), although to a lesser degree (test between 
both categories: z = 3.29, p < .01) than with reduced GH signaling 
(lnRR = −0.78, 95% CI [−0.97, −0.57]).
To understand whether the degree of life-span extension is 
related to the change in body mass, both across and within these 
different manipulation types, we tested if the change in body mass 
with a particular manipulation predicts the degree of life-span exten-
sion. This test would hint that life-span extension in these mouse 
models represents a direct trade-off with body size (as highlighted in 
(31)). When considering all data across all GH-IGF1 manipulations, 
the change in body weight in a particular model was a significant 
predictor of the degree of life-span extension (lnHR[slope of lnRR] = 1.01, 
95% CI [0.41, 1.62], Z  =  3.28, p  =  .001, QM1  =  10.7, p  =  .001, 
R2[m] = 71.97%; Figure 1D). However, this predictive effect of change 
in body weight was fully explained by the differences that occur 
between the different manipulation types (Figure 1D). When body 
mass change was included in a model that also includes a treatment 
category (either pituitary/GH or IGF1), the slope was substantially 
reduced and was no longer significant (lnHR[slope of lnRR] = 0.35, 95% 
CI [−0.65, 1.36], z = 0.70, p = .49). Indeed, within each treatment 
category change in body mass had no discernable effect (centered 
log response ratio: 0.03 ± SE = 0.90, z = 0.03, p = .97). The initial 
significant relationship between body weight change and degree of 
life-extension, when different hormonal manipulations are ignored, 
appears to be an example of Simpson’s paradox (32): when a trend 
appears across a broad set of data but this effect disappears (or in 
other situations can be reversed) when effects within different sub-
groups are taken into account. In this situation, while manipulations 
of reduced pituitary/GH signaling have greater effects on both body 
mass and life span than reduced IGF1 signaling, within either group-
ing there is no relationship between these two variables.
Life-span Extension and Baseline Cohort Life Span
Another quantitative measure that has been suggested to be impor-
tant in determining treatment effects in longevity studies is the life 
span of the control animals; for example, whether the average life 
span of the control group is small (eg, 500 days) or large (eg, 1,000 
days). It has been suggested that particular manipulations might 
rescue the high mortality effects of poor housing conditions (eg, 
infections or extreme temperature/humidity variation), or genetic 
backgrounds that have an increased susceptibility to particular dis-
eases, rather than generally impacting aging. It has also been high-
lighted that strains can differ in their activity of particular pathways 
that regulate the aging process and influence life span, including the 
GH-IGF1 axis (33), and thus manipulations of these pathways will 
have stronger effects in some backgrounds than others. Under these 
scenarios, larger life-span effects of a manipulation are expected in 
short-lived controls (10).
Xu et al. (9) provided a qualitative comparison of changes in life 
span with IGF1 manipulation in four different studies where each 
cohort differed in its control group life span, and suggested that 
reduced IGF1 signaling preferentially extends life span in short-lived 
strains. Simply examining the relationship between control group 
life span and degree of life-extension across studies, however, fails to 
account for regression to the mean. That is, if the life span of long 
and short-lived control cohorts differs purely because of random 
sample variance, then we would expect that subsequent treatment 
group life spans would be closer to the average (34), generating such 
a relationship as a statistical artifact. It is notable that for two strains 
examined by Xu et al. (9). differences in control strain life span were 
correlated with baseline levels of IGF1 signaling, and partial inhibi-
tion of IGF1R had a greater inhibitive effect on IGF1 and IRS acti-
vation in the strain that showed greatest life-extension. This finding 
suggests that these strain life spans could be a consequence of under-
ling differences in physiology rather than random sample variance. 
Nonetheless, because regression to the mean can lead to substantial 
artifactual relationships that have no biological meaning (34,35), we 
sought to account for this while exploring further the relationship 
proposed by Xu et al. (9).
If reduced IGF1 signaling preferentially extends the life span 
of short-lived strains we would expect a difference in variance for 
life span between control and treatment groups (35). Therefore we 
tested for differences in equality of variance for life span between 
treatment groups in each of our hormonal signaling categories. We 
note here that these tests assume underlying normality and a true 
estimator of repeatability. While median life span is usually close to 
normally distributed (as in the Gompertz), more sophisticated and 
accurate statistical methods are available for accounting for regres-
sion to the mean (36) but require a greater sample size than is avail-
able in this analysis. Such approaches in situations of greater sample 
size may help to validate or refute these hypotheses.
Within GH and IRS signaling groups we find no statistical evi-
dence of a relationship between the control group life span and 
the degree of life-span extension. There is no significant difference 
in the equality of variance between control and treatment groups 
(Supplementary Table S2) and no significant relationship is found 
even when simply regressing median life span of the control group 
against the change in median life span induced by the genetic manip-
ulation (GH: rs = −.41, p = .10, IRS: rs = .54, p = .13). In contrast, 
for the IGF1 grouping the variance is lower in the treatment groups’ 
median life spans compared to controls, in both males and females 
(Supplementary Table S2). The negative correlation between control 
group median life span and the increase in life span with IGF1 reduc-
tion is negative (correlation: rs = −.63, p = .01), which, when viewed 
along-side the reduction in variance, suggests that reduced IGF1 
signaling may preferentially extend life span in short-lived control 
cohorts that are exposed are exposed to some kind of stress (10) or 
have higher levels of IGF1 signaling (9).
Publication Bias
We examined publication bias through rank correlations of the 
summed sample size in a study against lnHR50, the life-span effect 
measured at median life span. Across the whole set this indicated 
potential bias (rs = .75, 95% CI 0.41–0.91), meaning that small stud-
ies tended to find a larger effect at median life span (Supplementary 
Figure S1). Within each treatment category there are also rela-
tionships between sample and effect size, although this appears 
weaker for the IGF1 group, where sample sizes are generally larger 
(Supplementary Figure S1; IRS [rs = 1, but note there were only three 
studies for this subgroup]; GH [rs = .79, 95% CI 0.08–0.97]; IGF1 
[rs = .41, 95% CI −0.60–0.92]). Unfortunately, the nature of this rel-
atively small set precludes any imputation of bias to correct for this 
possible effect, especially while analyzing the moderating variables.
4 Journals of Gerontology: BIOLOGICAL SCIENCES, 2017, Vol. 00, No. 00
Such publication bias suggests that the data included in this 
meta-analysis, and thus that published in the literature, may not 
provide an accurate representation of the true biological effect, and 
that tests of moderating factors across these studies (eg, sex, type of 
manipulation) could also be influenced by this or vice versa. We note, 
however, that the detection of publication bias in statistical terms is 
not proof that there was actual bias in publication (where studies 
that find smaller effects are less likely to be published), and we might 
speculate that expensive mouse life-span studies would be published 
regardless of their outcome. The relationship between sample size 
and effect size could instead be influenced by unknown moderat-
ing variables. For example, follow-up studies on mouse models like 
the Ames and Snell Dwarf mice are based on citations of previous 
work where dwarfs have been reported to live up to 50% longer 
(eg, see for an example of this citation (37)), and therefore in these 
follow-up studies authors begin with a smaller sample size as they 
expect a big effect. In follow-up studies exploring the role of IGF1 in 
mouse longevity, by contrast, where results have been less consistent, 
authors have specifically stated that they design their experiments 
with larger sample sizes because of this (10). These components of 
study design could explain differences in both sample size and effect 
size and crucially associated known and unknown moderating vari-
ables across the main treatment groups (Supplementary Figure S1), 
and similar effects within the GH grouping when considering studies 
on Ames and Snell Dwarfs compared to other GH manipulations 
(Supplementary Figure S2). However, such effects would not explain 
any relationships between sample size and effect size within treat-
ment groups, and/or where experiments have been designed without 
prior knowledge of potential effect sizes.
Overall, the effects reported in this article represent the current 
state of published knowledge on GH-IGF1-IRS signaling and longev-
ity, but the publication bias highlights that this published knowledge 
may not represent the true biological effect of these manipulations, 
across all laboratories and conditions. Our caution on publication 
bias warrants independent replication of these studies to alleviate 
concerns about such bias.
Discussion
Our results indicate that reduced somatotrophic signaling extends life 
span in mice. The degree of this life-extension, however, is dependent 
on the type of signal that is manipulated, with life-span extension 
(as assessed at median life span) across studies being greater and 
more consistent (lower heterogeneity) when GH/general pituitary 
signaling is reduced, rather than when IGF1 or IRS signaling com-
ponents are manipulated directly. Reduced GH/pituitary signaling 
robustly increases median life span, has a clear effect on vulnerability 
to die from ageing related causes (Gompertz parameter a), and is not 
dependent on sex or the control group’s median life span. Life-span 
extension with reduced IGF1 signaling, by contrast, is sex-specific, 
with females showing greater life-span extension than males, and in 
both sexes greater life-span extension is observed when the control 
cohort has a shorter life span. Our study of IRS mutants highlights 
substantial heterogeneity in the change in median life span, which is 
not explained by sex or the life span of the control group, although 
might be a consequence of lower replication across models and labo-
ratories compared to the data available for GH and IGF1.
Our analysis of life-extension via reduced IRS signaling (through 
genetic inhibition of IRS1 or IRS2 protein expression), also high-
lights that the mortality effects of this manipulation appear distinct, 
demographically, from life-span extension through reductions in 
GH and IGF1. Reduced IRS signaling reduces Gompertz parameter 
b and hence slows the rate of aging. We first note that our sam-
ple size for this analysis is small, with data comprised from three 
different studies and nine control-treatment survival comparisons. 
Additional replication of this reduction in the rate of aging with con-
siderable sample size within a single study may help to confirm this 
result, particularly in light of the potential publication bias that we 
highlight. Nonetheless, there are several reasons why reduced IRS 
signaling may affect mouse mortality differently to GH/IGF1 signal-
ing. Insulin receptor substrates are intra-cellular signaling kinases 
that are phosphorylated by signals from both the insulin and IGF1 
receptors. Genetically reduced IRS signaling will therefore decrease, 
or inhibit, some signaling responses that occur with IGF1R activa-
tion. However, since IRS proteins also promote various aspects of the 
insulin signaling cascade after phosphorylation by the insulin recep-
tor, including activation of Akt/PKB, reduced IRS signaling will also 
interfere with insulin signaling and glucose homeostasis (13). The 
direct role of alterations in insulin signaling in life-span extension is 
poorly understood: mouse models of life-extension can show both 
heightened and reduced insulin sensitivity and glucose homeostasis 
(38). Mice that are insulin sensitive can be short-lived, and mice that 
have reduced expression of the insulin receptor (IR), and are insu-
lin insensitive, have similar life spans to wild-types (although the 
study acknowledges a small sample size and a possible interactive 
effect with sex) (39). Another possibility is that reducing IRS signal-
ing increases mortality rates slightly early in life, but slows mortality 
late in life, which would appear to modulate the rate of aging. In line 
with this suggestion, a life-span study of mice with a genetic reduc-
tion of p110α PI3K activity, which is downstream of both the IR and 
IGF1 receptors, reported that this manipulation reduced mouse sur-
vival slightly early in life but increased survival after 500 days (40).
Results on the demography of mortality that we reveal in this 
study can also be qualitatively compared to results from several 
recent meta-analysis on life-span extension through reduced mTOR 
signaling (41) and dietary restriction (27,42). In relation to the 
slowed rate of aging observed with IRS signaling, the only other 
manipulation shown to consistently reduce the rate of aging in mice 
is dietary restriction. The similarity between these two manipula-
tions in patterns of mouse mortality might suggest that alterations in 
aspects of the insulin-signaling cascade could contribute to slowed 
aging with dietary restriction (27), and/or that these manipulations 
have similar effects on some causes of mouse death. Our results for 
changes in demography with reduced GH/pituitary signaling point to 
a consistent lowering of the mortality risk of mutant mice across life. 
We recently demonstrated that reduced mTORC1 signaling, through 
rapamycin or genetic manipulation, results in similar demographic 
responses (41). Concordantly, both pituitary and GH impaired 
mutants show reduced mTORC1 signaling (43,44), in fasted and fed 
states (43), and it has been suggested that this may contribute to life-
span extension in these models. The similar resultant demographic 
responses to these treatments would support this hypothesis.
Using meta-analysis, we also conducted a test of the hypothesis 
that body size trades-off against life span, and that relative changes 
in growth may relate to degree of life-span extension. If greater body 
weight change leads to incremental increases in life span, we would 
expect the two factors to correlate. Although there is substantial 
variation in the degree of body weight change within each of these 
hormonal manipulation groups, we find no statistically significant 
relationship between body weight change and degree of life-span 
extension—once the broad type of manipulation is taken into con-
sideration. This is consistent with two manipulative studies in Ames 
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(45) and Snell (46) Dwarf mice, where early life treatment with both 
GH and T4 combined substantially increased the body mass of these 
dwarfs but had relatively minor effects on the life-span phenotype 
(although see (37) for an example of a GH manipulation that did 
reduce life span in Ames Dwarf mice). These results suggest that life-
span extension with these manipulations is not simply a consequence 
of reducing costs associated with the anabolic actions of growth, 
and that manipulations of the GH-IGF1 axis are providing other 
anti-aging benefits, perhaps linked to their effects on stress resist-
ance (37), insulin sensitivity (47), or inflammation (48)—traits not 
directly linked to growth and body size.
It’s further notable that while reduced IGF1 signaling has a 
smaller effect on body mass than reduced GH signaling, these dif-
ferences in effects on body mass do not seem to explain why we 
observe a smaller degree of life-span extension when only IGF1 
signal is reduced. Thus, the effects of reduced GH signaling, spe-
cifically, may provide life-span benefits outside of its effects in 
reducing IGF1 production. The different effects of GH and IGF1 
on pathways and mechanisms of aging might also be sex-specific, 
as reduced IGF1 signaling provides a greater life-span benefit to 
females, while reduced GH signaling has a similar life-span effect 
in both sexes. Interestingly, partial inhibition of IGF1R enhances 
resistance to oxidative stress only in females (8,10), not males, sug-
gesting that IGF1 signaling may differently regulate some of the 
cellular processes linked to aging in females only. A greater under-
standing of the cellular processes that are differentially regulated by 
either GH or IGF1 manipulation, particularly in each sex, may pro-
vide mechanistic insights into the regulation of life span by soma-
totrophic signaling.
We hope that our review will stimulate future experimental 
and comparative research on the physiological causes for life-
span variation across mutant somatotrophic signaling models, 
and animals showing life-span extension. For example, data from 
tissue-specific GH receptor knockout animals is already revealing 
that GH’s life-span benefits may be generated independently of 
effects on circulating IGF1. GH’s main effects on circulating IGF1 
occur through its stimulatory effects on IGF1 secretion in the liver. 
Liver-specific GH receptor knockout mice show greatly reduced 
levels of circulating IGF1 (~90%) and reductions in body mass 
similar to that seen in IGF1 mutant mice (49). Yet they do not live 
longer than controls (43), suggesting that the life-span benefits of 
GH occur outside of liver-derived IGF1. A  contrasting example, 
brain-specific inhibition of either IGF1R (50) or IRS2 (15) has 
been reported to extend life span, suggesting that central actions 
of these signaling pathways may be important in the regulation of 
life span. Once sufficient data is available, meta-analytic compara-
tive assessments of life-span extension in tissue-specific and induc-
ible GH, IGF1, and IRS mice will help to reveal the specific tissues 
and life-periods contributing to life-span extension in the mouse 
models reviewed here.
Experimental Procedures
Search Protocol
We began by searching for published research on life-span extension 
with reduced GH, IGF1 or IRS signaling in mice by checking several 
published reviews that provide comprehensive summaries of life-
span extension with altered activity of these pathways (19,51,52). 
We then conducted additional searches using Web of Science and 
Google Scholar.
We included studies that manipulated the activity of somato-
trophic signaling axis globally, that is, without inhibition of gene 
expression in a particular tissue. This allowed us to use an unbi-
ased search protocol and also provided opportunity to split ani-
mals into broad moderator groups accorded to the type of signal 
manipulated. We also only included data from studies where data 
from the sexes was separated, because we were interested in the 
effects of sex, and in how these treatments influence demography. 
Inclusion of studies where data from the sexes are combined, even 
when they do not statistically differ in median life span, might 
skew the demographic data. We included manipulations of soma-
totrophic signaling at a number of different levels (Supplementary 
Data). We collected data from models with impaired pituitary 
signaling (ie, the Ames and Snell Dwarf mice) and GH signaling 
(either by inhibition of its production [eg, disruption of growth-
hormone releasing hormone], or its reception [eg, targeted GH 
receptor disruption]). We further included studies that reduced 
IGF1 signaling, either by reducing IGF1 detection (eg, IGF1R 
+/− mice), its bioactivity (eg, through knockout of IGF1 binding 
protein PAPPA), or it’s circulating production. We note here that 
we included data from liver-specific IGF1 knockout mice, since 
this reduces the majority (75%–80%) of IGF1 in circulation. We 
further collected data from studies of life span where expression 
of either insulin receptor substrate protein was impaired (eg, 
IRS1 and IRS2). We excluded IRS2−/− animals from this analysis 
because males die prematurely (13), from diabetes (53), and not 
directly from aging.
Data Extraction and Analysis
Raw individual survival data was used whenever possible. When 
unavailable, mortality was measured from survival curves. Gompertz 
models were then fitted using maximum likelihood estimation (54), 
and estimates of sampling variances were obtained from the CIs 
around the parameters fitted on the individual level data. For one 
study where there was some ambiguity in date of death for a small 
proportion of individuals (26) sampling variance was estimated 
through simulation (27). To assess overall effects on life span a haz-
ard ratio at median life span was calculated using the number of 
individuals died and at risk in both experimental groups, for which 
sampling variances are known (42). Meta-analyses were run on these 
hazard ratios at median life span and the hazard ratio of the two 
Gompertz parameters with treatment group (reduced GH signaling) 
over the control group—negative hazard ratio estimates indicate 
improved survival with the manipulation. Mixed effects (multi-
level) meta-analyses were conducted using the package “metafor” 
(55) in R (56), with study identifiers included as a random term. 
Heterogeneity in meta-analyses was assessed by a multilevel version 
of I2 (57). We tested for publication and reporting bias using rank 
tests of sample size against effect size.
Supplementary Material
Supplementary data are available at The Journals of Gerontology, 
Series A: Biological Sciences and Medical Sciences online.
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